Background : Fragile X-associated tremor/ataxia syndrome (FXTAS) is a newly identified neurodegenerative disorder due to intermediate expansion of in the 5 ′ untranslated region (UTR) of the Fragile X mental retardation 1 ( FMR1 ) gene. FXTAS is now considered to be one of the most common inherited neurodegenerative disorders in males. Objective : To examine the future of potential therapies for this late-onset disease. Methods : Examination of relevent literature. Results/conclusions : Accumulating evidence indicates that overproduced riboCGG repeats in the 5 ′ UTR of FMR1 mRNA are toxic. Recently, proteins that bind specifically to rCGG repeats were identified. Progress in understanding the molecular pathogenesis of FXTAS, plus the availability of different animal models are discussed.
Introduction
Expansion of trinucleotide repeats is the cause of many heritable human diseases such as Fragile X syndrome and Huntington's disease [1] [2] [3] . Expansion of trinucleotide repeats could occur in the exon region of a gene (for example Huntington's disease). This kind of expansion results in the generation of polypeptides with a poly-glutamine or poly-alanine stretch, which has been shown to be toxic [2] [3] [4] [5] . In Fragile X syndrome, the trinucleotide expansion occurs in the 5 ′ untranslated region (UTR), resulting in hypermethylation of the promoter region, and eventually, shutting down the transcription of the Fragile X mental retardation 1 ( FMR1 ) gene [6] . In the normal population, the CGG repeat number in the 5 ′ UTR of FMR1 gene is between 5 and 54, and an expansion to 200 or higher (full mutation) leads to Fragile X syndrome. Repeat numbers between 55 and 200 are called 'premutation'. Premutation was previously considered not to directly cause any human disorder, and only to pose an increased risk of expanding into a full mutation when passed to the next generation. Recently neurologists have started recognizing unique neurological symptoms that are associated with Fragile X premutation carriers, which are distinguished from Fragile X syndrome [7] [8] [9] [10] [11] . This newly identified disorder is named Fragile X-associated tremor/ataxia syndrome (FXTAS). Major symptoms of this disorder include intention or postural (action) tremor, cerebellar gait and limb ataxia and Parkinsonism [7] [8] [9] [10] [11] . Neurodegenerative features, such as intracellular inclusion bodies, have been identified from neuroimaging and postmortem brain tissue [12] [13] [14] .
It has been known that FMR1 mRNA level is elevated 5 -10 times in premutation carriers, while the FMR protein (FMRP) level is about normal [15] . This phenomenon leads us and others to argue that the excess of FMR1 mRNA with expanded CGG repeats in its 5 ′ UTR is toxic. Indeed riboCGG (rCGG) repeats have been shown to be toxic in human neural cell culture as well as in transgenic flies [16, 17] . In fly model of FXTAS, non-coding rCGG repeats have been further shown to cause the formation of inclusion bodies and lead to neurodegeneration, cellular hallmarks of FXTAS in patients [17] . Emerging evidence suggests that the RNA-mediated gain-of-function mechanism could underlie several additional inherited diseases, including myotonic dystrophy type 1 and 2 (DM1 and DM2), spinocerebellar ataxia type 8 (SCA8), and Huntington's disease-like syndrome 2 (HDL2) [18] .
As a new and possibly currently under-diagnosed disease, FXTAS is considered to be one of the most common heritable neurodegenerative disorders in males: 1 in 813 males in the general population are carriers of an FMR1 premutation with about 40% penetrance for males aged > 50 years [19] . Therefore, there is a great need to develop therapies to alleviate and cure this disease.
Perspective
Currently, there is no specific treatment for FXTAS to target the underlying pathological mechanism. Treatments to relieve specific symptoms are the main medical practice at present [19, 20] . 
Comprehensive research into the molecular mechanism of FXTAS is needed to aid the development of FXTAS therapies. This review concentrates on current understanding of molecular pathology and construction of animal models of FXTAS. How advances in these areas may aid the development of future therapy will then be discussed.
Recently, two studies published by this laboratory and others have advanced our understanding of the pathogenesis of FXTAS one step further by identifying proteins interacting specifically with rCGG repeats [21, 22] . Using biochemical and genetic approaches, three proteins, purine-rich element containing-protein α (Pur α ), heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 (two protein isoforms from one gene), and CUG vbinding protein 1(CUGBP1) were found to bind rCGG repeats either directly (Pur α and hnRNP A2/B1) or indirectly (CUGBP1, through interaction with hnRNA A2/B1) ( Figure 1 ) [21, 22] . Thus, there are protein complexes physically interacting with rCGG repeats. All these proteins are RNA-binding proteins, and have been shown to function in transcription, mRNA trafficking, splicing and translation. Interestingly, Pur α knockout mice appeared normal at birth, but developed severe tremors and spontaneous seizures at 2 weeks of age due to markedly reduced numbers of neurons in regions of the hippocampus and cerebellum [23] . The hypothesis is that over-produced rCGG repeats in FXTAS sequester these proteins from their normal cellular functions, contributing significantly to the pathology of this disorder. This idea is strongly supported by the fact that overexpressing either Pur α or hnRNA A2/B1 alleviated neurodegeneration in a fly model of FXTAS [21, 22] . These results provide direct insights into the development of future therapies. Presumably, drugs that specifically suppress the interaction between the rCGG repeats and the protein complexes would release these proteins from this requisition. Compounds boosting the expression or function of these proteins may also be found to be useful. Identifying further downstream RNA targets of these proteins is also crucial, and specific therapies based on their affected RNA targets in FXTAS may then be explored. rCGG repeats form, at least in vitro , double-stranded RNA hairpins ( Figure 1 ), which is a structural feature shared by most trinucleotide repeats [24] . This structure resembles the hairpin of microRNA precursors, and indeed has been shown to be processed by Dicer, core component of the RNA interference (RNAi) machinery [24] . Interestingly, crossing rCGG and rGCC, two complementary repeats each pathogenic by itself, into transgenic flies rescued phenotypes generated by each individual repeat [25] . This rescue relies on Argonaute 2 (AGO2), another core component of the RNAi machinery [25] . RNAi is now under enthusiastic pursuit as a great hope for therapies for many varieties of diseases [26] . Approaches to promote the degradation of rCGG repeats by the RNAi machinery would provide a new direction in exploring therapies of FXTAS. Small-interfering (si)GCC RNA oligonucleotides, constructs or viruses that could generate siGCC in cells may be applied to treat FXTAS. Compounds enhancing the processing of rCGG hairpins by RNAi machinery may be identified and found to be beneficial. It is also crucial to investigate whether the binding of Pur α , hnRNP A2/B1 and CUGBP1 to rCGG repeats depends on the hairpin structure. If the answer is positive, compounds that disrupt the rCGG hairpins would release the sequestering of these proteins, another possibility for attacking this disease. A caution that must be kept in mind is the possibility of side effects from these kinds of compounds. Careful research need to be performed to make sure each drug is rCGG repeats-specific.
Expert opinion
The concept that non-coding repeats in certain mRNAs can be pathogenic is relatively new. The etiology of FXTAS has now been traced to a toxic mRNA sequence. An ideal therapy for this disease would be one to neutralize or reduce significantly the presence of the toxic rCGG repeats, while keeping the FMRP level above the minimal requirement. Presently, this is not close to realization.
Animal models of FXTAS should give strong support to the development of specific therapies. By using the FXTAS fly model, we have already revealed and will continue to uncover aspects of the pathology of the rCGG repeats. This model can also be used directly in drug discovery. Currently, our laboratory is screening the library of small molecules using the FXTAS fly model (P Jin, unpublished data). Chemical compounds identified from these screens can be further investigated, and, there will still be a long wait before one, if any, of them eventually becomes a therapeutic drug. By identifying compounds known to target specific a biochemical pathway, this chemical biology approach could also give us indications regarding the pathology of rCGG repeats. To aid these efforts, we are constructing another invertebrate model of FXTAS, which expresses rCGG repeats in the nematode worm, Caenorhabditis elegans (G Shan and P Jin, unpublished). The C. elegans genome does encode an obvious FMR1 homologue. In this model, the pathology of rCGG repeats can be investigated independently without considering the role of FMRP. A mouse model of FXTAS is also available, in which both elevated Fmr1 mRNA levels and intranuclear inclusions were detected in neurons; both the number and the size of the inclusions were increased during the aging process, which correlates with the progressive character of FXTAS in humans [27] . Although all these models may not be ideal in terms of modeling the human phenotypes, they would complement each other and provide interfaces to work with this disease at the current stage.
Many features of FXTAS are still obscure. Like a lot of other neurodegenerative diseases, FXTAS is late onset. The pathology in the context of aging requires more investigation. Better understanding of this feature will provide new angle for therapy development and help to delay and maybe ease the symptoms. We are still unclear about how the toxic rCGG repeats lead to neural cell death. How rCGG repeats trigger the formation of the inclusion bodies in neurons and astrocytes, and neural cell loss in FXTAS patients requires more investigation. Understanding of these mechanisms would shed new light on future therapy development. Preventing the formation of the inclusion bodies and cell death will certainly offer another tactic for disease treatment.
More effort is in need to decode FXTAS, and hopefully excellent treatments and even a cure for this disease will emerge in the near future.
